{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:34:34Z","timestamp":1790008474794,"version":"4.0.1"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,10,6]],"date-time":"2006-10-06T00:00:00Z","timestamp":1160092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Although various studies have stressed the role of phosphatase and tensin homologue deleted on chromosome 10 (PTEN)\u2010PI3K\u2010AKT pathway in the progression of melanocytic lesions, little is known about the expression pattern of PI3K in these lesions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:\u2002<\/jats:bold>\n                    To investigate the expression pattern of PI3K in benign and dysplastic nevi, primary melanomas, and metastatic melanomas and the role of PTEN and PI3K in melanocytic tumor progression.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Tissue microarrays were constructed using formalin\u2010fixed, paraffin\u2010embedded archival tissue blocks from 89 melanocytic lesions: 17 benign nevi, 18 dysplastic nevi, 23 primary melanomas, and 31 metastatic melanomas. Expression of PTEN and PI3K (p85 and p110 subunits) was evaluated immunohistochemically, and the number of cells and labeling intensity were assessed semiquantitatively.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Both benign and dysplastic nevi showed strong cytoplasmic staining with PTEN, which was subsequently less in melanomas and completely lost in the metastatic lesions. Eleven of 17 (64%) benign nevi, seven of 10 (70%) dysplastic nevi, four of 23 (17%) primaries, and one of 31 (3%) visceral or lymph node metastasis showed strong positivity. Loss of PTEN expression from benign and dysplastic nevi to melanoma was statistically significant (p\u2003=\u20030.001). Although few cells showed reactivity for phosphoinositide 3\u2010kinase (PI3 kinase)\u2010p85 subunit, strong positivity was not detected in the cytoplasm of benign, malignant, or metastatic lesions, except for a single visceral metastasis. Three of 13 (23%) nevi showed positivity for the p110 subunit. No positivity was observed in the dysplastic nevi. Two of 22 (9%) melanomas, one of 14 (7%) visceral metastasis, and three of 12 (25%) lymph node metastasis showed strong positivity. There was no statistical difference in PI3 kinase expression in benign and malignant melanocytic lesions (p\u2003=\u20030.2).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:\u2002<\/jats:bold>\n                    PI3K is not overexpressed in melanocytic lesions.\n                  <\/jats:p>","DOI":"10.1111\/j.1600-0560.2006.00592.x","type":"journal-article","created":{"date-parts":[[2006,10,6]],"date-time":"2006-10-06T07:33:11Z","timestamp":1160119991000},"page":"220-225","source":"Crossref","is-referenced-by-count":15,"title":["Phosphoinositide 3\u2010kinase is not overexpressed in melanocytic lesions"],"prefix":"10.1111","volume":"34","author":[{"given":"Rajendra S.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Hafeez","family":"Diwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,6]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.30037"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.06.049"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2003.11.007"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208152"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3\u2010Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco I","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(96)80132-4"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2005.02.008"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcdb.2004.01.002","article-title":"PI 3\u2010kinase, Akt and cell survival","volume":"15","author":"Downward J","year":"2004","journal-title":"Semin Cell Dev Biol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(01)00271-6"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:APPT.0000045801.15585.dd"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.49.31163"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol\u20103 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome\u2010positive cells","volume":"86","author":"Skorski T","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_14_2","article-title":"Oncostatin M activates phosphatidylinositol\u20103\u2010kinase in Kaposi\u2019s sarcoma cells","volume":"9","author":"Soldi R","year":"1994","journal-title":"Oncogene"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(199702)64:2<182::AID-JCB2>3.0.CO;2-T"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201447"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004230100203"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.193"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-005-1577-9"},{"key":"e_1_2_5_21_2","article-title":"Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR\u2010positive melanomas: a role of suppression of the PI3K\u2010AKT pathway","author":"Ivanov VN","year":"2004","journal-title":"Oncogene"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206598"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.21.1820"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.22.13375"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.8.6.537"},{"key":"e_1_2_5_26_2","article-title":"Resistance to gefitinib in PTEN\u2010null HER\u2010overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3\u2032\u2010kinase\/Akt pathway signaling","volume":"9","author":"She QB","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02473-3"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10294"},{"key":"e_1_2_5_29_2","article-title":"Increased expression of integrin\u2010linked kinase is correlated with melanoma progression and poor patient survival","volume":"9","author":"Dai DL","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.168"},{"key":"e_1_2_5_31_2","article-title":"Loss of PTEN promotes tumor development in malignant melanoma","volume":"63","author":"Stahl JM","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1096502"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:APPT.0000045801.15585.dd"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.141"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81780-8"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2003.12.022"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107416200"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023777013659"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00110-0"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3460561"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0560.2006.00592.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0560.2006.00592.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T17:28:49Z","timestamp":1696958929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0560.2006.00592.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1111\/j.1600-0560.2006.00592.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0560.2006.00592.x","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,6]]}}}